Stock·NASDAQ·Technology
Axcelis Technologies Inc. (ACLS)
- Market cap
- $3.35B
- P/E
- 42.01
- Dividend yield
- 0.00%
- Street target
- $145.00median of 5 analysts
- 52-week range
- $73.60 $193.78
The short version
Where ACLS stands today, in four lines, and what CleaRank Financial AI makes of it.
ACLS at a glance
Axcelis Technologies Inc. (ACLS): Hold, 44/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($123.79 and $122.19).
- Earnings ACLS beat estimates in 6 of its last 6 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $6.5M and made no open-market purchases over the last 18 months.
- Valuation P/E of 42.0 against 35.1 for the Technology sector: broadly in line with peers (+20%).
Figures as of October 18, 2026.
CleaRank Financial AI
Axcelis Technologies Inc. (ACLS) carries a CleaRank rating of Hold and a model score of 44/100.
The biggest lift to the score comes from the earnings record, with EPS beating estimates in 6 of its last 6 reports and the most recent available report beating the estimate by 1.41%. Momentum pulls the score down most, as the 14-day RSI of 35.2 is in the bearish zone and the MACD line is negative. The trend is down, with the price 12.47% below its 50-day average of $123.79 and 11.33% below its 200-day average of $122.19. The price has still risen 29.57% over the past year.
Only on CleaRank
Figures we compute ourselves from ACLS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $108.35 is 12.5% below the 50-day simple moving average of $123.79.Price above its 200-day average ›
The price is 11.3% below the 200-day simple moving average of $122.19.50-day average above the 200-day ›
The 50-day average ($123.79) is 1.3% above the 200-day average ($122.19), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 29% of its 52-week range, between $73.60 and $193.78.
ACLS share price
Pick a period: each tab shows how far ACLS has moved over it, to the last close.
Today's trading
Where ACLS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/4P/E below the sector median ›
The trailing P/E of 42.01 is 19.7% above the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 4.10 is 46.0% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $92.8M on revenue of $866.1M, a net margin of 10.7%.Beat estimates in most recent reports ›
ACLS beat the EPS estimate in 6 of its last 6 reports.
Key statistics
The headline figures for ACLS.
As of October 18, 2026, ACLS trades at $108.35, with a market value of $3.35B and a P/E ratio of 42.01.
What the numbers say
CleaRank Financial AI's reading of ACLS's valuation, growth and risks.
ACLS trades at 42.01 times earnings, against a Technology sector median of 35.1. That puts the P/E 19.7% above the median, which is broadly in line with peers. On sales, the P/S of 4.10 sits 46.1% below the sector median of 7.6. The company carries a market value of $3.3B.
Revenue grew 10.60% in the latest year, which is 13.6 percentage points slower than the sector median of 24.2%. Net margin stands at 10.71% and operating margin at 9.43%. Return on equity of 8.89% sits below the sector median of 13.4%, and debt-to-equity of 0.07 completes the picture.
Axcelis Technologies Inc. (ACLS) beat expectations in the May 7, 2026 report, with EPS of $0.72 against the $0.71 that analysts had forecast. That was a 1.41% beat. The shares climbed 2.75% in the following session.
Across its last 6 reports, ACLS beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 3 of them. The May 6, 2025 report stands out among the earlier ones: a beat of 173.68%, after which the stock rose 6.20%. Analysts' average EPS estimate for this fiscal year is $4.11, which would be a decline of 15.9%, and $5.27 for next year (growth of 28.3%).
ACLS typically moves about 3.69% a day. While the price stays below both moving averages, the downtrend remains a risk in its own right. The stock is 44.09% below its 52-week high of $193.78. Insiders sold $6.5M of stock over the last 18 months and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, which makes them a weaker signal than buying would be.
ACLS against the Technology sector
How ACLS compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (20% difference), suggesting fair market pricing relative to industry standards.
Return vs XLK: Since May 6, 2025, ACLS has gained 98.1% against a gain of 71.7% for XLK.
Performance against XLK
ACLS and the Technology sector fund over the same days.
Revenue and earnings
How much ACLS sells, and how much of it becomes profit.
Revenue growth: Revenue fell 17.6% in FY2025 to $839M, from $1.0B a year earlier.
Profit margin: The net margin was 14.3% in FY2025, down from 19.7% the year before.
Profitable: ACLS earned $120M in FY2025.
Earnings reality check
Did ACLS beat what analysts expected, and how did the stock react?
Earnings record: ACLS beat the analyst estimate in 6 of the last 6 quarters.
Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| May 7, 2026after close | $0.71 | $0.72 | +1.41% | +2.75% | +1.88% |
| Nov 4, 2025after close | $1.00 | $1.21 | +21.00% | +4.89% | +6.30% |
| Aug 5, 2025after close | $0.71 | $1.13 | +59.15% | -2.94% | +4.24% |
| May 6, 2025after close | $0.38 | $1.04 | +173.68% | +6.20% | +14.94% |
| Feb 10, 2025after close | $1.25 | $1.54 | +23.20% | -12.25% | -6.10% |
| Nov 6, 2024after close | $1.43 | $1.49 | +4.20% | -0.97% | -9.36% |
Reports after May 7, 2026 are not yet in our data.
As of October 18, 2026, ACLS has beaten the analyst EPS estimate in 6 of its last 6 reported quarters and fell in the first trading session after 3 of those beats; its most recent report in our data, on May 7, 2026, came in 1.41% above the estimate and the stock moved +2.75% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 35.2, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 35.2 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ACLS
The score, the reasoning behind it, and what could move the price next.
Both moving averages sit above the price, the shape of a downtrend for ACLS: the price of $108.35 is 12.47% below the 50-day average ($123.79) and 11.33% below the 200-day average ($122.19). At 29% of its 52-week range, the price is 47.21% above the 52-week low of $73.60. The 50-day average itself is 1.31% above the 200-day average.
On momentum, the 14-day RSI reads 35.2, in the bearish zone, above the oversold line, with the MACD line negative. The short and long run point different ways: the price rose 4.43% over the past month, fell 20.58% over the past three months and rose 29.57% over the past year.
Earnings beat ›
The May 7, 2026 report beat the EPS estimate by 1.41%, and the share price rose 2.75% in the first session after it.
Source: Earnings report, May 7, 2026
Rating reaffirmed ›
B of A Securities kept its Underperform rating on June 23, 2026.
Source: Analyst action, B of A Securities, June 23, 2026
- Two levels matter most: the 200-day SMA at $122.19, which sits above the price, and the 52-week low at $73.60, which sits below it.
- A 14-day RSI of 35.2 falls in the bearish zone, and the MACD line is negative. Readings above 70 or below 30 point to stretched momentum.
- ACLS beat estimates in 6 of its last 6 reports. After the May 7, 2026 report, the share price rose 2.75% in the first session.
ACLS remains in a downtrend while it sits below both its 50-day average of $123.79 and its 200-day average of $122.19. A close back above the 200-day average would mark the first sign of repair. That 200-day SMA at $122.19 is the nearest hurdle above the price.
ACLS has a next support level at its 52-week low of $73.60, the first level below the price. The RSI is in the bearish zone, which argues against a fast rebound.
Technical indicators
Momentum and trend for ACLS, from its daily closes.
As of October 18, 2026, with ACLS at $108.35, its 14-day RSI is 35.2 (showing bearish momentum without being oversold), its 50-day simple moving average is $123.79 and its 200-day is $122.19.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ACLS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, ACLS's 1-year correlation of daily returns is +0.52 with S&P 500 (SPY), +0.59 with Nasdaq 100 (QQQ), +0.18 with Bitcoin (BTC) and +0.10 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
1 of 5 analysts rate it a buy or strong buy, 3 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $145.00 is 33.8% above the price.More buy ratings than three months ago ›
1 of 5 rate it a buy now, against 2 of 5 three months ago.
ACLS Wall Street View
12-month price targets
The price, $108.35, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 23, 2026 | B of A Securities | Maintains | Underperform |
As of October 18, 2026, 5 Wall Street analysts cover ACLS: 1 rate it a buy or strong buy, 3 a hold and 1 a sell or strong sell. Their 12-month price targets range from $140.00 to $198.00, with a median of $145.00, 33.8% above the price of $108.35.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ACLS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
ACLS moves about 3.7% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ACLS tends to move, against the market and on its own.
The long record
ACLS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 3.69% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 78.8%, from July 2023 to April 2025; the price is still 46.0% below that peak.Most 1-year holds ended higher ›
64% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $78,800, against $41,793 in the S&P 500 (SPY).
ACLS Drawdowns & Recovery
As of October 18, 2026, ACLS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -78.8% (July 2023 to April 2025); it is still 46.0% below that peak, and 64% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ACLS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ACLS beat the S&P 500 over this period: $78,800 against $41,793.
A $10,000 investment in ACLS in October 2016 would be worth about $78,800 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ACLS, and which have not.
Strongest month, June: an average of +8.61%, up in 6 of 10 years.
Weakest month, February: an average of -1.26%, up in 5 of 10 years.
This month, October: has averaged -0.09%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ACLS's strongest calendar month has been June (average +8.61%, up in 6 of 10 years) and its weakest February (average -1.26%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ACLS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ACLS today could grow to about $27,553 by 2036 in the base case, with a 90th-percentile outcome near $209,035 and a 10th-percentile outcome around $3,632. Projections are statistical simulations, not guarantees.
ACLS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $163 for ACLS by 2030 in the base case, from $108 today (1.5x over 4 years). The 10th-percentile path ends near $45.11. These are outcomes of a Monte Carlo simulation run on ACLS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $63.18 | $120 | $228 | |
| 2028 | $53.62 | $133 | $328 | |
| 2029 | $48.40 | $147 | $446 | |
| 2030 | $45.11 | $163 | $585 | |
| 2031 | $42.92 | $180 | $754 |
Method: a lognormal simulation of ACLS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. ACLS is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
ACLS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought ACLS shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 18, 2026, ACLS insiders reported 23 open-market sales worth $6.5M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Necip Sayiner
Director
|
Sell | 1.6K | $249.7K |
| Jun 2, 2026 | Robert John Mahoney
Officer
|
Sell | 1.2K | $179.3K |
| May 27, 2026 | Todd Sutton
Officer
|
Sell | 2.0K | $320.0K |
| May 22, 2026 | Eileen Evans
General Counsel
|
Sell | 926 | $144.0K |
| May 22, 2026 | Dennis Thomas St
Director
|
Sell | 900 | $139.8K |
| May 21, 2026 | Gerald M Blumenstock
Officer
|
Sell | 1.2K | $177.3K |
| May 20, 2026 | Christopher Tatnall
Officer
|
Sell | 1.2K | $174.6K |
| May 19, 2026 | John Thomas Kurtzweil
Director
|
Sell | 3.5K | $485.8K |
| May 19, 2026 | Gregory B Graves
Director
|
Sell | 3.2K | $456.7K |
| May 19, 2026 | Jeanne Quirk
Director
|
Sell | 1.8K | $250.9K |
| May 15, 2026 | Gerald M Blumenstock
Officer
|
Grant | 5.5K | - |
| May 15, 2026 | Tzu Yin Chiu
Director
|
Grant | 1.4K | - |
| May 15, 2026 | Eileen Evans
General Counsel
|
Grant | 7.8K | - |
| May 15, 2026 | Gregory B Graves
Director
|
Grant | 1.4K | - |
| May 15, 2026 | John Thomas Kurtzweil
Director
|
Grant | 1.4K | - |
| May 15, 2026 | Russell J Low
Chief Executive Officer
|
Grant | 38.9K | - |
| May 15, 2026 | Robert John Mahoney
Officer
|
Grant | 3.9K | - |
| May 15, 2026 | Jeanne Quirk
Director
|
Grant | 1.4K | - |
| May 15, 2026 | Gregory F Redinbo
Officer
|
Grant | 6.2K | - |
| May 15, 2026 | David Ryzhik
Chief Financial Officer
|
Grant | 3.1K | - |
| May 15, 2026 | Necip Sayiner
Director
|
Grant | 1.4K | - |
| May 15, 2026 | Dennis Thomas St
Director
|
Grant | 1.4K | - |
| May 15, 2026 | Todd Sutton
Officer
|
Grant | 1.2K | - |
| May 15, 2026 | Christopher Tatnall
Officer
|
Grant | 7.0K | - |
| May 15, 2026 | Jorge Luis Titinger
Director
|
Grant | 1.4K | - |
| May 14, 2026 | Todd Sutton
Officer
|
Sell | 2.6K | $421.9K |
| May 14, 2026 | Gerald M Blumenstock
Officer
|
Sell | 1.0K | $164.8K |
| May 13, 2026 | Gregory F Redinbo
Officer
|
Sell | 2.9K | $463.7K |
| May 13, 2026 | Jorge Luis Titinger
Director
|
Sell | 2.0K | $328.3K |
| May 12, 2026 | Robert John Mahoney
Officer
|
Sell | 2.3K | $363.5K |
| May 6, 2026 | Russell J Low
Chief Executive Officer
|
Sell | 7.5K | $1.2M |
| May 1, 2026 | Russell J Low
Chief Executive Officer
|
Sell | 1.2K | $172.7K |
| Apr 1, 2026 | Russell J Low
Chief Executive Officer
|
Sell | 1.2K | $117.0K |
| Mar 24, 2026 | Russell J Low
Chief Executive Officer
|
Sell | 1.2K | $112.0K |
| Feb 20, 2026 | Jorge Luis Titinger
Director
|
Sell | 1.0K | $80.0K |
| Jan 15, 2026 | Robert John Mahoney
Officer
|
Grant | 1.7K | - |
| Dec 17, 2025 | Jorge Luis Titinger
Director
|
Sell | 2.0K | $172.1K |
| Dec 11, 2025 | Gerald M Blumenstock
Officer
|
Sell | 3.0K | $271.4K |
| May 20, 2025 | John Thomas Kurtzweil
Director
|
Sell | 1.7K | $104.2K |
| May 15, 2025 | Gerald M Blumenstock
Officer
|
Grant | 12.3K | - |
| May 15, 2025 | Tzu Yin Chiu
Director
|
Grant | 3.6K | - |
| May 15, 2025 | James Gordon Coogan
Chief Financial Officer
|
Grant | 24.6K | - |
| May 15, 2025 | Eileen Evans
General Counsel
|
Grant | 14.3K | - |
| May 15, 2025 | Gregory B Graves
Director
|
Grant | 3.6K | - |
| May 15, 2025 | John Thomas Kurtzweil
Director
|
Grant | 3.6K | - |
| May 15, 2025 | Russell J Low
Chief Executive Officer
|
Grant | 61.5K | - |
| May 15, 2025 | Jeanne Quirk
Director
|
Grant | 3.6K | - |
| May 15, 2025 | Gregory F Redinbo
Officer
|
Grant | 12.3K | - |
| May 15, 2025 | Necip Sayiner
Director
|
Grant | 3.6K | - |
| May 15, 2025 | Dennis Thomas St
Director
|
Grant | 3.6K | - |
| May 15, 2025 | Christopher Tatnall
Officer
|
Grant | 12.3K | - |
| May 15, 2025 | Jorge Luis Titinger
Director
|
Grant | 3.6K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.